Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | UBE2M | P61081 | 1/20 | 0.34 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14040011 | 0.85 | LIMK2 (0.38) | HTR4LIMK2BCHE | |
| SCHEMBL21069439 | 0.84 | BCHE (0.39) | CCR5LIMK2BCHEACHEKMT2A | |
| SCHEMBL15017085 | 0.82 | CNR2 (0.38) | LIMK2KMT2A | |
| SCHEMBL19558802 | 0.81 | LIMK2 (0.38) | LIMK2BCHE | |
| SCHEMBL23560059 | 0.79 | ACHE (0.42) | HTR4EPHX1EPHX2ACHESMN1; SMN2 | |
| SCHEMBL24438464 | 0.79 | ALOX5 (0.39) | EPHX1LIMK2 | |
| SCHEMBL23568560 | 0.78 | OPRM1 (0.40) | EPHX1EPHX2SMN1; SMN2 | |
| SCHEMBL22181604 | 0.78 | NR1H2 (0.38) | CCR5BCHEACHE | |
| SCHEMBL21574018 | 0.77 | HTR2C (0.42) | EPHX1 | |
| SCHEMBL8911411 | 0.77 | HTR2C (0.42) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HTR4 3714/4885EPHX1 1684/4885EPHX2 1890/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HTR4 3714/4885EPHX1 1684/4885EPHX2 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.